Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1971 2
1972 1
1973 2
1974 3
1975 6
1976 6
1977 10
1978 9
1979 9
1980 12
1981 15
1982 22
1983 35
1984 40
1985 52
1986 52
1987 41
1988 49
1989 85
1990 131
1991 133
1992 121
1993 140
1994 163
1995 138
1996 182
1997 187
1998 172
1999 179
2000 247
2001 259
2002 317
2003 376
2004 324
2005 341
2006 356
2007 372
2008 344
2009 380
2010 393
2011 438
2012 472
2013 507
2014 534
2015 618
2016 570
2017 596
2018 642
2019 680
2020 701
2021 751
2022 783
2023 732
2024 328

Text availability

Article attribute

Article type

Publication date

Search Results

12,301 results

Results by year

Filters applied: . Clear all
Page 1
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. Jagasia MH, et al. Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18. Biol Blood Marrow Transplant. 2015. PMID: 25529383 Free PMC article.
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with furt …
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic …
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions.
Martinez-Cibrian N, Zeiser R, Perez-Simon JA. Martinez-Cibrian N, et al. Blood Rev. 2021 Jul;48:100792. doi: 10.1016/j.blre.2020.100792. Epub 2020 Dec 26. Blood Rev. 2021. PMID: 33386151 Review.
Graft-versus-host disease (GvHD) was first described in 1959, since then major efforts have been made in order to understand its physiopathology and animal models have played a key role. ...Attention should be paid to graft-versus-leukemia, infections …
Graft-versus-host disease (GvHD) was first described in 1959, since then major efforts have been made in order t …
Clinical Application and Potential of Fecal Microbiota Transplantation.
Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Ooijevaar RE, et al. Annu Rev Med. 2019 Jan 27;70:335-351. doi: 10.1146/annurev-med-111717-122956. Epub 2018 Nov 7. Annu Rev Med. 2019. PMID: 30403550 Review.
The current state of knowledge indicates that dysbiosis of the gut microbiota is implicated in several disorders in addition to C. difficile infection. Randomized controlled studies have shown FMT to be somewhat effective in treating ulcerative colitis, irritable bowel syn …
The current state of knowledge indicates that dysbiosis of the gut microbiota is implicated in several disorders in addition to C. difficile …
Stem Cell Therapies in Clinical Trials: Progress and Challenges.
Trounson A, McDonald C. Trounson A, et al. Cell Stem Cell. 2015 Jul 2;17(1):11-22. doi: 10.1016/j.stem.2015.06.007. Cell Stem Cell. 2015. PMID: 26140604 Free article. Review.
Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of conditions using a variety of stem cell types. ...Limbal stem cells have been registered as a product for eye burns in Europe and mesenchymal stem cells have been ap …
Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of conditions using a variet …
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.
Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly J, Cordonnier C; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). Maertens JA, et al. J Antimicrob Chemother. 2018 Dec 1;73(12):3221-3230. doi: 10.1093/jac/dky286. J Antimicrob Chemother. 2018. PMID: 30085172 Review.
Posaconazole is strongly recommended for preventing invasive mould disease post-engraftment but only when graft-versus-host disease (GvHD) was accompanied by other risk factors such as its severity, use of an alternative donor or when unresponsive to s …
Posaconazole is strongly recommended for preventing invasive mould disease post-engraftment but only when graft-versus-host …
Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE, Wampole M, Oberoi K. Ringheim GE, et al. Front Immunol. 2021 Nov 3;12:662223. doi: 10.3389/fimmu.2021.662223. eCollection 2021. Front Immunol. 2021. PMID: 34803999 Free PMC article. Review.
We investigated the BTK specificity and toxicity profiles, drug properties, disease associated signaling pathways, clinical indications, and trial successes and failures for the 13 BTK inhibitor drug candidates tested in phase 2 or higher clinical trials repr …
We investigated the BTK specificity and toxicity profiles, drug properties, disease associated signaling pathways, clinical indicatio …
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers ME, Schultz KR, Vogelsang G, Pavletic S. Lee SJ, et al. Biol Blood Marrow Transplant. 2015 Jun;21(6):984-99. doi: 10.1016/j.bbmt.2015.02.025. Epub 2015 Mar 19. Biol Blood Marrow Transplant. 2015. PMID: 25796139 Free PMC article.
In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Criteria Working Group recommended several measures to document serial evaluations of chronic GVHD organ involvement. ...Ancillary measures are …
In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Cri …
Graft-versus-host disease.
Bron D. Bron D. Curr Opin Oncol. 1994 Jul;6(4):358-64. doi: 10.1097/00001622-199407000-00006. Curr Opin Oncol. 1994. PMID: 7803536 Review.
Combinations of drugs such as methotrexate, cyclosporin A, and prednisone have reduced the incidence of graft-versus-host disease (GVHD) to 20% to 30%. However, GVDH remains a major complication (up to 90%) following allogeneic bone marrow transplantat …
Combinations of drugs such as methotrexate, cyclosporin A, and prednisone have reduced the incidence of graft-versus-host …
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. Filipovich AH, et al. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56. doi: 10.1016/j.bbmt.2005.09.004. Biol Blood Marrow Transplant. 2005. PMID: 16338616 Free article.
First, it standardizes the criteria for diagnosis of chronic graft-versus-host disease (GVHD). Second, it proposes a new clinical scoring system (0-3) that describes the extent and severity of chronic GVHD for each organ or site at any given tim …
First, it standardizes the criteria for diagnosis of chronic graft-versus-host disease (GVHD). Second, it propos …
Chronic graft-versus-host disease.
Lee SJ, Vogelsang G, Flowers ME. Lee SJ, et al. Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33. doi: 10.1053/bbmt.2003.50026. Biol Blood Marrow Transplant. 2003. PMID: 12720215 Free article. Review.
Chronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allogeneic stem cell transplantation. ...It also provides a comprehensive listing of the published clinical trials aimed at prevention and primary treatment …
Chronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allogeneic stem cell tra …
12,301 results
You have reached the last available page of results. Please see the User Guide for more information.